Best Peptide for Weight Loss: What the Evidence Shows

Disclosure: This post contains affiliate links. We may earn a commission if you purchase through our links, at no extra cost to you.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The best peptide for weight loss, judged by FDA approval and large human trials, is a GLP-1 medicine: semaglutide (Wegovy) or tirzepatide (Zepbound). Those are the approved peptide drugs with the largest weight-loss trials, thousands of people each. For popular compounded and gray-market peptides such as sermorelin, ipamorelin, BPC-157 and AOD-9604, the human evidence for weight loss is thin or missing. I’m Judy, I’m not a doctor, and this page is a read of the labels, trials and FDA pages I link, not a ranking of products to buy.

Table of Contents

Which peptide is best for weight loss?

Semaglutide and tirzepatide have the largest randomized weight-loss results of the peptide medicines with a weight-management label. Zepbound is a prescription injection, and Wegovy comes as an injection and, on its current label, a tablet. Both are labeled for use alongside a reduced-calorie diet and more physical activity. Tirzepatide acts on the GIP receptor as well as the GLP-1 receptor, according to its label (Zepbound label, DailyMed).

Everything else in the “best peptides” lists falls into one of three groups: approved drugs for a different problem, drugs still in trials, or unapproved compounds sold with little or no human data. The sections below take them in that order.

What do the semaglutide and tirzepatide trials show?

STEP 1: semaglutide 2.4 mg

STEP 1 enrolled 1,961 adults with obesity, or overweight plus a weight-related condition, and no diabetes. After 68 weeks of weekly semaglutide 2.4 mg plus lifestyle support, the average body weight change was minus 14.9 percent, compared with minus 2.4 percent on placebo. Nausea and diarrhea were the most common side effects, and 4.5 percent of the semaglutide group stopped treatment because of gastrointestinal events (Wilding et al., New England Journal of Medicine, 2021). Novo Nordisk, the maker, funded the trial.

SURMOUNT-1: tirzepatide

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight plus a weight-related complication, and no diabetes. After 72 weeks, average weight change was minus 15.0 percent at 5 mg, minus 19.5 percent at 10 mg and minus 20.9 percent at 15 mg, compared with minus 3.1 percent on placebo. The most common side effects were gastrointestinal and mostly mild to moderate (Jastreboff et al., New England Journal of Medicine, 2022). Eli Lilly, the maker, supported it.

Both are averages across a trial population, and neither trial is a promise for you. Judy’s note, my experience and not medical advice: I was 47 and about 68 pounds overweight when I started GLP-1 injections in May 2024, and I lost 31 pounds in 14 months. The trial averages above are percent of starting body weight, so they do not convert directly into pounds, and my 31 pounds is one person’s result that can land above or below any average.

My Ozempic for weight loss page goes deeper on the semaglutide numbers, and Ozempic vs Wegovy explains how the two brand names differ.

What do the Wegovy and Zepbound labels say they are approved for?

The Wegovy injection label on DailyMed (version published June 30, 2026) lists use with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and children 12 and older with obesity, and in adults with overweight plus at least one weight-related condition. It also lists reducing major cardiovascular events in adults with established heart disease and obesity or overweight (Wegovy label, DailyMed).

The Zepbound label (version published September 2, 2026) lists the same kind of weight indication for adults, plus moderate to severe obstructive sleep apnea in adults with obesity (Zepbound label, DailyMed).

Both labels carry a boxed warning about thyroid C-cell tumors. In rodents the drugs caused these tumors, and it is unknown whether they do in humans. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A prescriber has to weigh that against your history, which is not something a listicle can do.

Is retatrutide the next best peptide for weight loss?

Retatrutide is a triple agonist for the GIP, GLP-1 and glucagon receptors, and it is still an investigational drug. In a phase 2 trial of 338 adults, average weight change at 48 weeks was minus 24.2 percent at the 12 mg dose, compared with minus 2.1 percent on placebo, and heart rate rose in a dose-dependent way before declining (Jastreboff et al., New England Journal of Medicine, 2023). In the phase 3 TRIUMPH-1 trial of 2,339 adults with obesity and no diabetes, the average change over 80 weeks was minus 25.0 percent at 12 mg versus minus 3.9 percent on placebo (Jastreboff et al., New England Journal of Medicine, published online September 29, 2026). Lilly funded both.

Trial results are not approval. BioPharma Dive reported on July 23, 2026 that Lilly planned to file with the FDA in the first quarter of 2027 (BioPharma Dive). The FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, says retatrutide cannot be used in compounding under federal law and that it has not been found safe and effective for any condition (FDA).

A DailyMed search for retatrutide on October 20, 2026 returned twelve listings, all from one overseas e-commerce company, and the one I opened is marked “Export only.” None came from the trial sponsor. A listing on DailyMed does not mean FDA approval.

Does sermorelin help with weight loss?

I did not find human trial evidence that it does. Sermorelin was sold as Geref, and in 2013 the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness (Federal Register, March 4, 2013). That is a statement about why it left the market, not an endorsement for weight loss. A DailyMed search for sermorelin on October 20, 2026 returned zero labels.

The best adult data I can point to is a small placebo-controlled trial of a close relative, not sermorelin itself. Ten women and nine men aged 55 to 71 injected the growth hormone releasing hormone analog nightly for 16 weeks. Growth hormone and IGF-I rose, but body weight was unaffected (Khorram et al., Journal of Clinical Endocrinology and Metabolism, 1997). For the full picture, see my sermorelin therapy guide.

What about ipamorelin, CJC-1295 and tesamorelin?

Ipamorelin and CJC-1295 are growth hormone axis peptides, and the FDA’s compounding pages are cautious about them. On its page of bulk drug substances that may present significant safety risks (current as of April 22, 2026), the FDA lists ipamorelin acetate in category 2 under its 503B interim policy, noting a published report of serious adverse events including death when ipamorelin was given intravenously for gastric motility. The same page lists CJC-1295 among substances nominated but withdrawn and says the FDA has identified serious adverse events associated with it, including increased heart rate and a systemic vasodilatory reaction (FDA). Sermorelin is not named on that page.

Tesamorelin is the exception that tells you something. Egrifta SV is FDA approved to reduce excess abdominal fat in adults with HIV and lipodystrophy, and its label says it is not indicated for weight loss management because it has a weight neutral effect (Egrifta SV label, DailyMed). That is an approved peptide in this group, and its own label says it is not a weight-loss drug.

What does the human evidence say about BPC-157 and AOD-9604?

BPC-157 is marketed mostly for injury recovery, not for weight loss. A 2025 systematic review found 36 studies, 35 of them preclinical and one a small retrospective clinical study of knee pain, and no clinical safety data (Vasireddi et al., HSS Journal, 2025). A 2026 review that searched through June 1, 2026 found only three small human studies (30 people in total) of poor quality and rated the certainty of evidence very low (Poolton et al., Acta Orthopaedica Belgica, 2026). Neither review tested weight loss.

For AOD-9604, a fragment of growth hormone, the FDA page above says compounded drugs containing it may pose significant risk for immunogenicity for certain routes of administration, that the agency has identified no or only limited safety-related information, and that it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear. The FDA lists both BPC-157 and AOD-9604 under bulk drug substances nominated but withdrawn.

A 2026 narrative review of GH-axis peptides sold as “research compounds” describes evidence tiers running from regulatory-grade randomized trials to a complete absence of human studies, and notes uncertainty about product composition and dose in unregulated supply chains (Dominikowski et al., Frontiers in Endocrinology, 2026).

What does the FDA say about compounded and gray-market peptides?

The FDA states that compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed. It also says a compounded drug might be appropriate when a patient’s medical need cannot be met by an approved drug, and it lists telehealth red flags: claims that a compounded drug is the same as an approved drug, prices that seem too good to be true, and no screening by a licensed doctor before medicine ships (FDA).

A 2026 sports medicine review describes a parallel “gray market” of unapproved peptides operating largely outside regulatory oversight, and says rigorous human safety data are scarce for many of them (Mendias and Awan, Sports Medicine, 2026).

Do peptide stacks work for weight loss?

The 2026 Frontiers review cited above says stacking practices and the composition of products from unregulated supply chains are uncertain. The weight-loss trials covered on this page tested one drug at a time, each used with a diet and activity plan.

How do you get a GLP-1 peptide medicine the legal way?

A licensed clinician decides whether Wegovy or Zepbound fits your health history, and a licensed pharmacy fills it. Telehealth can be one route, and my how to get GLP-1 online guide covers the steps, costs and red flags.

If you and a clinician decide a GLP-1 is worth discussing, GobyMeds is one telehealth service that offers compounded semaglutide and compounded tirzepatide, along with Wegovy and Zepbound. This is an affiliate link, and I may earn a commission if you sign up through it. The link opens one generic GobyMeds account sign-up page used for all of its products, not a page for a particular drug. Its site says all prescriptions require a consultation with a licensed provider, so a provider must approve before anything ships. As of October 20, 2026, GobyMeds describes its weight loss program as “compounded GLP-1 programs.” Compounded drugs are not FDA approved, results vary, and outcomes are not guaranteed.

Who should check with a clinician before using any peptide?

Everyone. The label warnings above are the short list: a personal or family history of medullary thyroid carcinoma or MEN 2 rules out Wegovy and Zepbound. A clinician can also tell you whether a medication for weight loss is appropriate at all, which is something no ranking of products can do. Exercise and food still matter, since both labels describe use alongside a reduced-calorie diet and more physical activity.

This page is general information, not medical advice. I am not a doctor or registered dietitian, so talk to your doctor or prescriber before you start, change or stop any medicine, and never buy a prescription peptide from a seller that does not require a prescription.

Frequently Asked Questions

Do peptides work for weight loss?

Some do, and most do not have the evidence. Semaglutide and tirzepatide produced average weight loss of 14.9 percent over 68 weeks and 15.0 to 20.9 percent over 72 weeks in large trials of adults with obesity or overweight. For the unapproved peptides sold online, the human weight-loss data are small or absent.

Which peptides are FDA approved for weight loss?

Wegovy (semaglutide) and Zepbound (tirzepatide) carry weight-management indications on their labels, in adults with obesity or with overweight plus a weight-related condition. Saxenda (liraglutide) also carries a weight-management label. Imcivree (setmelanotide) is labeled only for specific rare genetic or hypothalamic obesity. Retatrutide, sermorelin, ipamorelin, BPC-157 and AOD-9604 are not approved for weight loss.

Is retatrutide available yet?

It is still investigational. Phase 3 results are published, and the sponsor was reported to plan an FDA filing in early 2027. The FDA says it cannot be used in compounding, so a product sold as retatrutide today is not an approved medicine.

Are peptide injections from online sellers safe?

The FDA says it does not review compounded drugs for safety, effectiveness or quality, and it flags sellers that skip screening by a licensed doctor. A seller that does not require a prescription is outside the route the FDA describes.

Can peptides replace diet and exercise?

Not according to the labels. Both Wegovy and Zepbound are indicated in combination with a reduced-calorie diet and increased physical activity.

Sources

Best Peptide for Weight Loss: What the Human Evidence Shows